{
    "relation": [
        [
            "",
            "Nevirapine (NVP) Plus Truvada",
            "Atazanavir Plus Ritonavir (ATV/r) Plus Truvada"
        ],
        [
            "Description",
            "Nevirapine 200 mg bis in die (BID)",
            "Atazanavir 300 mg plus ritonavir 100 mg quaque die (QD)"
        ]
    ],
    "pageTitle": "Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00552240?sect=Xk0156&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042990114.79/warc/CC-MAIN-20150728002310-00315-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 872818299,
    "recordOffset": 872804911,
    "tableOrientation": "VERTICAL",
    "textBeforeTable": "Reporting Groups There was a 28 day screening period where a genotype report was run. If patients were resistant to any of the study medication, they were not to be randomized into the study. Patients also needed to meet all inclusion/exclusion criteria in order to be eligible. 154 patients were enrolled but 2 were not treated, leaving 152 in full analysis set. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Patients were recruited from 28 Sep 2007 through 23 Mar 2009 at 18 sites throughout the US. The sites were comprised of medical centers or private practice physicians. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: tenofovir DF 300 mg QD Drug: emtricitabine 200 mg QD",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Nevirapine (NVP) Plus Truvada \u00a0 \u00a0 Atazanavir Plus Ritonavir (ATV/r) Plus Truvada \u00a0 STARTED \u00a0 \u00a0 75 [1] \u00a0 77 [1] COMPLETED \u00a0 \u00a0 51 \u00a0 \u00a0 59 \u00a0 NOT COMPLETED \u00a0 \u00a0 24 \u00a0 \u00a0 18 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 9 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 9 \u00a0 Protocol Violation \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 Lost to Follow-up \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}